masthead-news.jpg

News & Events

2018 Nordic Precision Medicine Forum

Join us at the 2nd Annual Nordic Precision Medicine Forum and learn how we are doing our part to help the conversation on personalized healthcare

Crowne Plaza Copenhagen Towers | Copenhagen, Denmark | March 20 - 21, 2018

Read More

Category: Events
Posted on:

HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

TUCSON, Ariz., Jan. 23, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting the underwriting discounts and commissions and offering expenses.

Read More

Category: Press Releases
Posted on:

HTG Molecular Diagnostics Announces Pricing of Public Offering of Common Stock

TUCSON, Ariz., Jan. 18, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the pricing of an underwritten public offering of 12,100,000 shares of its common stock at a price to the public of $2.90 per share. All of the shares are being sold by HTG. The gross proceeds from the offering are expected to be $35.1 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on January 23, 2018, subject to customary closing conditions. In addition, HTG has granted the underwriters a 30-day option to purchase up to 1,815,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

HTG anticipates using the net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures and research and development, sales and marketing and general and administrative expenses.

Read More

Category: Press Releases
Posted on:

HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock

TUCSON, Ariz., Jan. 16, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that it intends to offer and sell, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. All of the shares are being offered by HTG. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners LLC and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering. LifeSci Capital LLC is acting as co-manager for the offering. HTG expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock.

Read More

Category: Press Releases
Posted on:

HTG Molecular Announces Third Statement of Work for New Clinical Assay Development Program

TUCSON, Ariz., Jan. 16, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced it has entered into a third statement of work for a new clinical assay development program under its Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN, N.V. (NYSE:QGEN). Work for the new development program will begin immediately.

Read More

Category: Press Releases
Posted on:

2018 Molecular Pathology in Oncology

Join HTG at the Molecular Pathology in Oncology at stand 7 and learn more about our HTG EdgeSeq PATH Assay. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of markers when tissue availability is limited.

Biomedical Research Centre | The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research | London, UK | March 15, 2018

Read More

Category: Events
Topics: Molecular Profiling, PATH Assay
Posted on:

HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance

TUCSON, Ariz., Jan. 04, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2017, and provided initial full year 2018 revenue guidance.

Preliminary 4th Quarter and Full Year 2017 Unaudited Financial Results and Revenue Guidance for 2018:

  • Total revenue for the fourth quarter of 2017 is expected to be between $6.9 and $7.2 million, an increase of 373% to 394% over the fourth quarter of 2016.

  • Total revenue for the full year 2017 is expected to be between $13.8 and $14.1 million, an increase of 169% to 175% over total revenue for the full year 2016.

  • Collaboration revenue drove fourth quarter and full year 2017 revenue. Operating expenses for the fourth quarter are expected to be slightly higher than operating expenses in the third quarter of 2017 on an absolute dollar basis. Gross margin and net loss in the fourth quarter are expected to be improved over the third quarter of 2017, primarily as a result of collaboration profit-sharing revenue expected to be recognized in the fourth quarter.

  • Cash and cash equivalents are expected to be approximately $10.0 million as of December 31, 2017.

  • HTG is providing initial revenue guidance for the year ending December 31, 2018 in the range of $20.0 to $25.0 million.

Read More

Category: Press Releases
Posted on:

HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany

TUCSON, Ariz. and DARMSTADT, Germany, Dec. 26, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications today announced a new Master Collaboration Agreement for translational programs with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The Master Collaboration Agreement complements the previously announced Master Companion Diagnostic Agreement with Merck KGaA, Darmstadt, Germany and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the United States and Canada.

Read More

Category: Press Releases
Posted on:

HTG Molecular Diagnostics to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018

TUCSON, Ariz., Dec. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

Read More

Category: Press Releases
Topics: HTG
Posted on:

Page last updated February 23, 2018